Foundation One has written an excellent study on Metaplastic Breast Caner and Genomic Profiling.
The exact title is a bit of a mouthful but here goes: Comprehensive Genomic Profiling of Metaplastic Breast Carcinoma By Next Generation Sequencing Reveals Frequent Actionable Genomic Abnormalities and New Routes to Targeted Therapies
But I love it as it outlines the exact pathology of 20 patients with an average age of 61 - with metaplastic breast cancer. It details:
The most common actionable GA were mutations, amplifications and homozygous deletions of PIK3CA (40%), PTEN (25%) and CDKN2A/B (20%), EGFR (10%) and HRAS (10%) with AKT3, BRCA2, CCND1, CCND2, CCNE1, CDK4, FBXW7, FGFR1, NF1, PIK3R1 and SRC altered in a single case.
Please find it here: http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&sqi=2&ved=0CB8QFjAA&url=http%3A%2F%2Ffoundationone.com%2Fdocs%2FMetaplasticBrCA_USCAP2014_Poster_JSR.pdf&ei=UEOXU4KeGIH0OY2tgLgG&usg=AFQjCNFtW26bIfIU1ybXstv69aGoDoN2Vw&sig2=cOjc70JexVx3oD_su8JkQw&bvm=bv.68693194,bs.1,d.ZGU